Curative Biotechnology, Inc. Names Cary Sucoff to Board of Directors
BOCA RATON, Fla., May 12, 2022 /PRNewswire/ -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Cary Sucoff has joined its Board of Directors as an independent director. With over 35 years of legal and securities industry experience, Cary Sucoff has participated in the financing of over one hundred public and private companies and is currently on the boards of, or an advisor to, six healthcare and biotechnology companies. Mr. Sucoff is an expert in legal, compliance, corporate strategy, and capital markets and has chaired or sat on audit, compensation, nominating/governance, and special committees.
- BOCA RATON, Fla., May 12, 2022 /PRNewswire/ -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Cary Sucoff has joined its Board of Directors as an independent director.
- Since 2011, Mr. Sucoff has owned and operated Equity Source Partners LLC, an advisory and consulting firm.
- In addition, Mr. Sucoff currently serves as an advisor to:
Sapience Therapeutics, Inc. - a Phase 1/2 Biotech company focusing on Glioblastoma. - Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases.